Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Debt (2020 - 2025)

Historic Total Debt for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $424342.0.

  • Gain Therapeutics' Total Debt fell 1417.2% to $424342.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $424342.0, marking a year-over-year decrease of 1417.2%. This contributed to the annual value of $438504.0 for FY2024, which is 2277.82% down from last year.
  • Gain Therapeutics' Total Debt amounted to $424342.0 in Q3 2025, which was down 1417.2% from $451467.0 recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Total Debt peaked at $722542.0 during Q1 2021, and registered a low of $424342.0 during Q3 2025.
  • Moreover, its 5-year median value for Total Debt was $578274.0 (2023), whereas its average is $568748.8.
  • Its Total Debt has fluctuated over the past 5 years, first plummeted by 589.05% in 2023, then plummeted by 2277.82% in 2024.
  • Gain Therapeutics' Total Debt (Quarter) stood at $694294.0 in 2021, then decreased by 13.09% to $603393.0 in 2022, then fell by 5.89% to $567850.0 in 2023, then dropped by 22.78% to $438504.0 in 2024, then decreased by 3.23% to $424342.0 in 2025.
  • Its Total Debt stands at $424342.0 for Q3 2025, versus $451467.0 for Q2 2025 and $427597.0 for Q1 2025.